Welcome to Beacon Equity Research. Today is Friday, 14 September 2007  
 Home     Covered Companies     News and Commentary     Our Team     Ratings     Resources     Contact Us    
 
Untitled Document
 
Untitled Document Affiliates
Untitled Document
Untitled Document
Untitled Document
Untitled Document
Untitled Document
Untitled Document
Untitled Document
Untitled Document


Immune Response (OTCBB: IMNR) Secures Partners for MS Clinical Trials
Immune Response Corporation recently announced on that it has entered into an agreement with Accelsiors CRO & Consultancy Services, a clinical research organization with extensive experience in conducting multiple sclerosis (MS) trials, to oversee the 200-patient Phase II trial of NeuroVax, an investigational T-cell receptor peptide vaccine for the treatment of MS. Immune went on further to announce that in November they will hold a clinical trial meeting in Budapest, Hungary to discuss plans for a multi-center trial. This trial will also be a double-blind placebo control test to further investigate the viability of NeuroVax as a treatment for MS. The trial will enroll around two hundred patients with relapsing-remitting MS and it will examine the effectiveness of NeuroVax as compared to the placebo. The primary objective of the study is to compare the cumulative number of new gadolinium enhancing lesions, a key marker of MS disease activity, using MRI scans at 24, 32, 40, and 48 weeks. Secondary objectives rang from remission calculations to safety concerns surrounding any new, experimental drug. In addition to partnering with the clinical research organization, Immune Response has also partnered with NeuroRx Research, a company with special expertise in advanced MRI acquisition and analysis techniques, to oversee professional management of all MRI-related study activities.

The Immune Response Corporation is an immuno- pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate disease pathogen-specific immune responses aimed at slowing or halting the rate of disease progression. Both drugs currently show promise in their effectiveness, and if successful, should drive the company's stock higher.
 
< Prev   Next >

 
Copyright 2007 Beacon Equity Research